替罗非班在老年女性NSTACS冠脉治疗中的应用  

Application of Tirofiban in The Treatment of Coronary NASTACS in Older Women

作　　者：韩滨[1] 崔冬辰 王海生[2] 武瑞兵[2] 邓秀玲[2] 苑红[2] 叶纪诚[2] 王鹏翔[2] 聂永祯[3] 张建宇[2] 

机构地区：[1]武警内蒙古总队医院心内科,内蒙古呼和浩特010010 [2]内蒙古医科大学基础医学院,内蒙古呼和浩特010110 [3]内蒙古医科大学附属人民医院麻醉科,内蒙古呼和浩特010020

出　　处：《内蒙古医学杂志》2015年第6期649-652,共4页Inner Mongolia Medical Journal

基　　金：内蒙古医科大学青年创新基金(YKD2013QNCX006)

摘　　要：目的观察替罗非班在老年女性NSTACS的冠脉介入治疗过程中疗效及安全性。方法将107例年龄大于60岁女性NSTACS患者随机分成两组,对照组采用先负荷量治疗再维持量给药,试验组采用仅给予维持量给药治疗。观察两组36 h^30 d期间主要心脏不良事件(MACE)发生情况。结果与对照组相比,试验组PCI术后30 d MACE事件及心功能指标无统计学差异(P>0.05),而相关出血并发症发生率降低(P<0.01)。结论老年女性ACS患者应用低剂量替罗非班安全有效。Objective To observe the effect of tirofiban on coronary artery in elderly women NSTACS in- tervention efficacy and safety of treatment process. Methods 107patients aged over 60 years old female patients with NSTACS were randomly divided into two groups, the control group using the load dose at the beginning, then using aequum does maintain therapeutic, the experimental group was given to the treatment of maintenance dose. To observe major adverse cardiac events （MACE） occurrence during the period of 36h to 30d between the two groups. Results Compared with the control group, no significant difference between the experimental group PCI after 30 d MACE events andcardiac function indexes（P 〉 0.05） and hemorrhage associated with lower incidence of complications（P 〈 0.01）. Conclusion The use of low doses of older women is safe and effective in patients with ACS tirofiban.

关 键 词：急性冠脉综合征 替罗非班 疗效 安全性 

分 类 号：R543.3[医药卫生—心血管疾病]